This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease

This study has been withdrawn prior to enrollment.
(no subjects recruited)
Sponsor:
Collaborators:
Harvard University
GlaxoSmithKline
Information provided by (Responsible Party):
Tom Jaksic, Boston Children's Hospital
ClinicalTrials.gov Identifier:
NCT01191177
First received: August 27, 2010
Last updated: June 20, 2017
Last verified: June 2017
  Purpose
The purpose of this study is to investigate the usefulness of oral fish oil(Lovaza)in normalizing liver function in patients who have parenteral nutrition associated liver disease. The investigators believe that patients who take oral fish oil will normalize liver function faster than those who do not

Condition Intervention Phase
Liver Disease Short Bowel Syndrome Drug: Lovaza (omega-3-acid ethyl ester) Dietary Supplement: Corn oil Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: An Initial Trial of Enteral Fish Oil Supplementation in the Treatment of Parenteral Nutrition-associated Liver Disease in Patients With Short Bowel Syndrome

Resource links provided by NLM:


Further study details as provided by Tom Jaksic, Boston Children's Hospital:

Primary Outcome Measures:
  • Normalization of ALT
    The primary aim is to examine the efficacy of Lovaza, when compared to placebo, on normalizing liver function, as measured primarily by amino alanine transferase (ALT). The investigators believe that patients in the Lovaza group will normalize ALT faster than in the placebo group.


Secondary Outcome Measures:
  • Normalization other liver function tests and inflammatory status
    The investigators believe that Lovaza will result in faster reduction of the serum levels of the following markers: total bilirubin, aspartate amino transferase (AST), alkaline phosphatase, gamma glutamyl transpeptidase (GGTP) & C-reactive protein (CRP).


Enrollment: 0
Study Start Date: January 2011
Estimated Study Completion Date: January 2012
Estimated Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Lovaza group
Patients randomized to this group will receive Lovaza 1gram per kilogram of body weight, not exceeding 4grams a day
Drug: Lovaza (omega-3-acid ethyl ester)
supplied as 1gram transparent soft-gelatin capsules filled with yellow oil, dosage is 1gram per kilogram of body weight per day, not exceeding 4grams per day until normalization of liver function test
Other Name: fish oil
Placebo Comparator: Placebo group
Patients randomized to this group will receive corn oil supplement 1gram per kilogram of body weight, not exceeding 4grams per day
Dietary Supplement: Corn oil
1 gram per kilogram body weight per day, not exceeding 4 grams

Detailed Description:
This is designed as a randomized placebo controlled trial of oral fish oil (Lovaza) in normalizing parenteral nutrition associated liver disease.
  Eligibility

Ages Eligible for Study:   up to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of parenteral nutrition(PN)administration >4weeks
  • PN associated liver disease from intestinal failure
  • ability to take full enteral feed
  • body weight equal or greater than 3kg
  • elevated ALT level twice of that normal(ALT>84)at the time PN is weaned off

Exclusion Criteria:

  • Hemodynamic instability
  • renal failure
  • suspected congenital obstruction of the hepatobiliary system
  • diagnosis hepatitis A, B, or C
  • diagnosis of alpha 1-antitrypsin deficiency
  • diagnosis of cytomegalovirus infection
  • diagnosis of HIV
  • children in care
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01191177

Locations
United States, Massachusetts
Children's Hospital Boston
Boston, Massachusetts, United States, 02115
Sponsors and Collaborators
Boston Children’s Hospital
Harvard University
GlaxoSmithKline
Investigators
Principal Investigator: Tom Jaksic, MD, PhD Children's Hopsital Boston
  More Information

Responsible Party: Tom Jaksic, W. Hardy Hendren Professor of Surgery, Harvard Medical School, Boston Children's Hospital
ClinicalTrials.gov Identifier: NCT01191177     History of Changes
Other Study ID Numbers: 09-02-0066
Study First Received: August 27, 2010
Last Updated: June 20, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Tom Jaksic, Boston Children's Hospital:
oral fish oil
Lovaza
Omega-3-acid supplementation

Additional relevant MeSH terms:
Syndrome
Liver Diseases
Short Bowel Syndrome
Disease
Pathologic Processes
Digestive System Diseases
Malabsorption Syndromes
Intestinal Diseases
Gastrointestinal Diseases
Postoperative Complications

ClinicalTrials.gov processed this record on August 17, 2017